Borrelia burgdorferi Antibodies

Santa Cruz Biotechnology features a diverse variety of Borrelia burgdorferi monoclonal antibodies for research focused on understanding Lyme disease and its causative agent, Borrelia burgdorferi. Borrelia burgdorferi Antibodies are compatible with multiple experimental applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Borrelia burgdorferi is a spirochete bacterium that causes Lyme disease, which can lead to severe health complications if left untreated. Understanding the interactions between Borrelia burgdorferi and the host immune response is essential for developing effective diagnostics and therapeutics. The study of Borrelia burgdorferi is crucial for advancing knowledge of vector-borne diseases and improving public health outcomes. Research into Borrelia burgdorferi continues to reveal new insights about bacterial persistence and immune evasion strategies. Investigating the molecular mechanisms of Borrelia burgdorferi infection helps identify potential therapeutic targets and biomarkers. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of Lyme disease pathogenesis and develop improved treatment strategies.